Ibezapolstat (ACX-362E)
Clostridioides difficile Infection (CDI)
Phase 2bActive
Key Facts
Indication
Clostridioides difficile Infection (CDI)
Phase
Phase 2b
Status
Active
Company
About Acurx Pharmaceuticals
Acurx Pharmaceuticals is a micro-cap, clinical-stage biotech developing novel antibiotics for urgent public health threats. Its lead program targets C. difficile infection and is in Phase 2b development. The company highlights a recent New England Journal of Medicine article advocating for a single pivotal trial for FDA approval, which could be a strategic consideration for its development pathway. Leadership has a track record in antibiotic biotechs, including the sale of Dipexium Pharmaceuticals.
View full company profileTherapeutic Areas
Other Clostridioides difficile Infection (CDI) Drugs
| Drug | Company | Phase |
|---|---|---|
| Aptorum Microbiome Therapeutics | Aptorum Group | Pre-clinical |
| CRS3123 | Crestone | Phase 2 |